

Vectormune HVT-AIV Concentrate and solvent for suspension for injection

Authorised

- Turkey herpesvirus, strain rHVT/AI-H5 (FC126, cell-associated), expressing haemagglutinin gene of Avian influenza virus subtype H5, Live

Product identification

Medicine name:

Vectormune HVT-AIV Concentrate and solvent for suspension for injection

Active substance:

Turkey herpesvirus, strain rHVT/AI-H5 (FC126, cell-associated), expressing haemagglutinin gene of Avian influenza virus subtype H5, Live

Target species:

Chicken (one day-old chick)

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Turkey herpesvirus, strain rHVT/AI-H5 (FC126, cell-associated), expressing haemagglutinin gene of Avian influenza virus subtype H5, Live
Presentation_strength:2 500 - 12 000 PFU/dose Reference:HSE Index:0

Pharmaceutical form:

Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

-

Chicken (one day-old chick)

- Meat and offal. 0 day
zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Ampoule (glass), Package_size:1 ampoule, Content:1000 doses

Packaging:Ampoule (glass), Package_size:1 ampoule, Content:2000 doses

Packaging:Ampoule (glass), Package_size:1 ampoule, Content:4000 doses

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Applications in exceptional circumstances (Article 25 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Ceva Sante Animale

Marketing authorisation date:

28/03/2025

Manufacturing sites for batch release:

Ceva-Phylaxia Zrt.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

28/03/2025

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 8/12/2025

[Download](#)

ema-puar-v6288-vectormunehvtaiv-initial-en.pdf